Olema Oncology Competitors and Similar CompaniesClear all

Olema Oncology's competitors and similar companies include PharmaCyte Biotech, OncBioMune Pharmaceuticals, Briacell and Agios Pharmaceuticals.

	Olema Oncology Olema Oncology (also known as Olema Pharmaceuticals) is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers.	PharmaCyte Biotech PharmaCyte Biotech is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes.	OncBioMune Pharmaceuticals OncBioMune specializes in innovative cancer research.	Briacell Briacell is a clinical-stage biotech company that focuses on immuno-oncology and develops personalized immunotherapy for cancer.	Agios Pharmaceuticals Agios Pharmaceuticals is a biopharmaceutical company discovering and developing therapeutics for cancer metabolism.
Founding Date	Founding Date 2007	Founding Date 1996	Founding Date 2005	Founding Date 2004	Founding Date 2008
Type	Type Public	Type Public	Type Public	Type Public	Type Public
Tags	Tags Healthcare biotech drug development oncology	Tags Healthcare biotech cannabis diabetes drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma therapy women's health	Tags Healthcare drug development oncology pharma
Locations	Locations San Francisco, US HQ San Francisco, US	Locations Laguna Hills, US HQ	Locations Baton Rouge, US HQ	Locations West Vancouver, CA HQ Berkeley, US New York, US	Locations Cambridge, US HQ
Employees	Employees 9630% increase	Employees 4	Employees 3	Employees 16	Employees 53611% increase
Valuation ($)	Valuation ($) 679.2 m	Valuation ($) 14.7 m	Valuation ($) 8.7 b	Valuation ($) 30.2 m	Valuation ($) 2.7 b
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) N/A	Revenue (est.) $124.7k (FY, 2023)	Revenue (est.) N/A	Revenue (est.) $54m (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods $126.2k (FY, 2023)	Cost of goods N/A	Cost of goods $6.3m (FY, 2025)
Gross profit	Gross profit N/A	Gross profit N/A	Gross profit $480.6k (FY, 2023)	Gross profit N/A	Gross profit $47.7m (FY, 2025)
Net income	Net income ($162.5m) (FY, 2025)	Net income $30.7m (FY, 2025)	Net income ($30.9m) (FY, 2023)	Net income ($26.6m) (FY, 2025)	Net income ($412.8m) (FY, 2025)